{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:43:57Z","timestamp":1794613437165,"version":"4.9.1"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pharmthera.2021.107971","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T22:57:37Z","timestamp":1629845857000},"page":"107971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Lessons from S1P receptor targeting in multiple sclerosis"],"prefix":"10.1016","volume":"230","author":[{"given":"Emanuela","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107971_bb0005","doi-asserted-by":"crossref","first-page":"577353","DOI":"10.1016\/j.jneuroim.2020.577353","article-title":"An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta1 and fingolimod therapy","volume":"347","author":"Acar","year":"2020","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0010","first-page":"1","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0015","doi-asserted-by":"crossref","first-page":"13659","DOI":"10.1523\/JNEUROSCI.1353-15.2015","article-title":"Downregulation of sphingosine 1-phosphate receptor 1 promotes the switch from tangential to radial migration in the OB","volume":"35","author":"Alfonso","year":"2015","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0020","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1084\/jem.20092210","article-title":"S1P1 receptor directs the release of immature B cells from bone marrow into blood","volume":"207","author":"Allende","year":"2010","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jneuroim.2015.06.006","article-title":"Fingolimod does not enhance cerebellar remyelination in the cuprizone model","volume":"285","author":"Alme","year":"2015","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2016.03.012","article-title":"The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration","volume":"279","author":"Anastasiadou","year":"2016","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: Risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev-immunol-081519-083952","article-title":"Finding a way out: S1P signaling and immune cell migration","volume":"38","author":"Baeyens","year":"2020","journal-title":"Annual Review of Immunology"},{"issue":"10 Supplement","key":"10.1016\/j.pharmthera.2021.107971_bb0050","article-title":"Effect of ceralifimod (ONO-4641), a sphingosine-1-phosphate receptor-1 and -5 agonist, on magnetic resonance imaging outcomes in patients with multiple sclerosis: Interim results from the extension of the DreaMS study","volume":"82","author":"Bar-Or","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40268-020-00316-1","article-title":"Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis","volume":"20","author":"Bascunana","year":"2020","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0060","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mus.25733","article-title":"Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability","volume":"56","author":"Berry","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"15 Supplement","key":"10.1016\/j.pharmthera.2021.107971_bb0065","article-title":"Siponimod penetrates, distributes and acts on the central nervous system: Translational insights","volume":"94","author":"Bigaud","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0070","first-page":"278982","article-title":"Differentiated pharmacokinetic\/pharmacodynamic (PK\/PD) profiles for Siponimod (BAF312) versus Fingolimod","volume":"2019","author":"Bigaud","year":"2019","journal-title":"ECTRIMS Online Library, Sep 11"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2016.03.012","article-title":"Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFbeta in patients with multiple sclerosis","volume":"70","author":"Blumenfeld","year":"2016","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.msard.2019.06.016","article-title":"Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire","volume":"34","author":"Blumenfeld-Kan","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.stem.2015.09.003","article-title":"Adult mammalian neural stem cells and neurogenesis: Five decades later","volume":"17","author":"Bond","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/cpdd.4","article-title":"Tolerability and pulmonary pharmacodynamic effects during treatment initiation of once-daily oral fingolimod in subjects with moderate asthma","volume":"2","author":"Boulton","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pharmthera.2021.107971_bb0095","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: A 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/nan.12048","article-title":"Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions","volume":"40","author":"Brana","year":"2014","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cellular Microbiology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0110","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI136068","article-title":"FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages","volume":"130","author":"Bryan","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/1759091414558416","article-title":"Convergent regulation of neuronal differentiation and Erk and Akt kinases in human neural progenitor cells by lysophosphatidic acid, sphingosine 1-phosphate, and LIF: Specific roles for the LPA1 receptor","volume":"6","author":"Callihan","year":"2014","journal-title":"ASN Neuro"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0120","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000693","article-title":"Impact of treatment on cellular immunophenotype in MS: A cross-sectional study","volume":"7","author":"Cellerino","year":"2020","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/1352458514551456","article-title":"Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients","volume":"21","author":"Chiarini","year":"2015","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0130","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0135","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1073858416685690","article-title":"CXCL12\/CXCR4\/CXCR7 chemokine axis in the central nervous system: Therapeutic targets for remyelination in demyelinating diseases","volume":"23","author":"Chu","year":"2017","journal-title":"Neuroscientist"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0308-6","article-title":"FTY720 attenuates excitotoxicity and neuroinflammation","volume":"12","author":"Cipriani","year":"2015","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-0922-6","article-title":"Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury","volume":"14","author":"Cipriani","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: A 12-month follow-up study","volume":"9","author":"Claes","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0160","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/1352458518789884","article-title":"Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study","volume":"25","author":"Cohen","year":"2019","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: The 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fimmu.2020.00635","article-title":"Siponimod (BAF312) activates Nrf2 while hampering NFkappaB in human astrocytes, and protects from astrocyte-induced neurodegeneration","volume":"11","author":"Colombo","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.24217","article-title":"Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide","volume":"76","author":"Colombo","year":"2014","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0180","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","article-title":"Benefit-risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis","volume":"77","author":"Comi","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0185","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0190","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00415-017-8642-5","article-title":"Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: An 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)","volume":"264","author":"Comi","year":"2017","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0195","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI73408","article-title":"Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility","volume":"124","author":"Cruz-Orengo","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0200","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cpdd.424","article-title":"Determination of seminal concentration of fingolimod and fingolimod-phosphate in multiple sclerosis patients receiving chronic treatment with fingolimod","volume":"7","author":"David","year":"2018","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0205","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/eji.201343312","article-title":"S1PR5 is pivotal for the homeostasis of patrolling monocytes","volume":"43","author":"Debien","year":"2013","journal-title":"European Journal Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0210","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1073\/pnas.1206093109","article-title":"Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome","volume":"109","author":"Deogracias","year":"2012","journal-title":"Proceedings. National Academy of Sciences. United States of America"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0215","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","article-title":"Advances in oral immunomodulating therapies in relapsing multiple sclerosis","volume":"19","author":"Derfuss","year":"2020","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0220","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.msard.2016.05.015","article-title":"Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials","volume":"8","author":"Derfuss","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0225","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000157","article-title":"Myeloid cells as target of fingolimod action in multiple sclerosis","volume":"2","author":"Di Dario","year":"2015","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2018.08.002","article-title":"Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo","volume":"96","author":"Dominguez-Villar","year":"2019","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0235","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/eji.200939858","article-title":"S1P3 confers differential S1P-induced migration by autoreactive and non-autoreactive immature B cells and is required for normal B-cell development","volume":"40","author":"Donovan","year":"2010","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0240","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000240","article-title":"Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations","volume":"3","author":"Dooley","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0245","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-133","article-title":"Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier","volume":"9","author":"van Doorn","year":"2012","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.11.022","article-title":"S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate","volume":"141","author":"Drouillard","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0255","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4049\/jimmunol.1701278","article-title":"Human naive and memory T cells display opposite migratory responses to sphingosine-1 phosphate","volume":"200","author":"Drouillard","year":"2018","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0260","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/glia.22949","article-title":"S1P1 deletion in oligodendroglial lineage cells: Effect on differentiation and myelination","volume":"64","author":"Dukala","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0265","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2010.08.006","article-title":"Differential responses of human microglia and blood-derived myeloid cells to FTY720","volume":"230","author":"Durafourt","year":"2011","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-0882-x","article-title":"Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes","volume":"14","author":"Dusaban","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.179","article-title":"Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory","volume":"5","author":"Efstathopoulos","year":"2015","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2019.00217","article-title":"Fingolimod alters tissue distribution and cytokine production of human and murine innate lymphoid cells","volume":"10","author":"Eken","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0285","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: A single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0290","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.107.127183","article-title":"Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis","volume":"323","author":"Foster","year":"2007","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0300","article-title":"Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia","author":"Francis","year":"2020","journal-title":"Brain Imaging and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0305","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamaneurol.2014.1065","article-title":"Fingolimod for the treatment of intracerebral hemorrhage: A 2-arm proof-of-concept study","volume":"71","author":"Fu","year":"2014","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0310","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.devcel.2012.08.005","article-title":"The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2","volume":"23","author":"Gaengel","year":"2012","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0315","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s12035-017-0468-8","article-title":"Identification of sphingosine 1-phosphate receptor subtype 1 (S1P1) as a pathogenic factor in transient focal cerebral ischemia","volume":"55","author":"Gaire","year":"2018","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-018-1323-1","article-title":"Sphingosine 1-phosphate receptor subtype 3 (S1P3) contributes to brain injury after transient focal cerebral ischemia via modulating microglial activation and their M1 polarization","volume":"15","author":"Gaire","year":"2018","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0325","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ni.2730","article-title":"Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation","volume":"14","author":"Garris","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0330","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cellsig.2014.03.029","article-title":"Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling","volume":"26","author":"Gatfield","year":"2014","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0686-4","article-title":"Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis","volume":"13","author":"Gentile","year":"2016","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0340","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0345","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri","year":"2017","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-57114-2","article-title":"Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis","volume":"10","author":"Ghadiri","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0355","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.03-0910fje","article-title":"The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors","volume":"18","author":"Graler","year":"2004","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0365","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1177\/1352458514564589","article-title":"Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis","volume":"21","author":"Haas","year":"2015","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0370","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2004-06-2075","article-title":"FTY720 suppresses humoral immunity by inhibiting germinal center reaction","volume":"104","author":"Han","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0375","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1471-4159.2003.02219.x","article-title":"Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells","volume":"88","author":"Harada","year":"2004","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0380","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bph.12207","article-title":"Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes","volume":"169","author":"Healy","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: A double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Science & Medicine"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0390","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0393-6","article-title":"Fingolimod induces neuroprotective factors in human astrocytes","volume":"12","author":"Hoffmann","year":"2015","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0395","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.intimp.2015.11.024","article-title":"Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice","volume":"30","author":"Hou","year":"2016","journal-title":"International Immunopharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107971_bb0400","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10571-020-00856-9","article-title":"FTY720 modulates microglia toward anti-inflammatory phenotype by suppressing autophagy via STAT1 pathway","volume":"41","author":"Hu","year":"2020","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0405","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1126\/science.aam5809","article-title":"S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense","volume":"359","author":"Huang","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0410","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP trial): A double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0415","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","article-title":"Edg8\/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival","volume":"25","author":"Jaillard","year":"2005","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0420","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/glia.20576","article-title":"Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells","volume":"55","author":"Jung","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0425","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/MCB.01465-06","article-title":"Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons","volume":"27","author":"Kajimoto","year":"2007","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0430","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458517728343","article-title":"Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis","volume":"24","author":"Kappos","year":"2018","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0435","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0440","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0445","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0450","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: Dose-blinded, randomized extension of the phase 2 BOLD study","volume":"73","author":"Kappos","year":"2016","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0455","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0460","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1096\/fj.10-173203","article-title":"Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model","volume":"25","author":"Kim","year":"2011","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0465","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/glia.23272","article-title":"Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination","volume":"66","author":"Kim","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0470","doi-asserted-by":"crossref","first-page":"29367","DOI":"10.1074\/jbc.M403937200","article-title":"The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis","volume":"279","author":"Kono","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0475","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0480","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1111\/j.1600-6143.2005.01085.x","article-title":"The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo","volume":"5","author":"Lan","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0485","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clinph.2014.05.031","article-title":"Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis","volume":"126","author":"Landi","year":"2015","journal-title":"Clinical Neurophysiology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0490","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0495","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0500","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.4049\/jimmunol.1201810","article-title":"Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3","volume":"190","author":"Lewis","year":"2013","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0505","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0286-8","article-title":"Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and\/or 3","volume":"12","author":"Li","year":"2015","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0510","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni.1743","article-title":"The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR","volume":"10","author":"Liu","year":"2009","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0515","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/ni.1939","article-title":"The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells","volume":"11","author":"Liu","year":"2010","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0520","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2011-10-388892","article-title":"Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice","volume":"119","author":"Lorvik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061515","article-title":"The S1P-S1PR Axis in neurological disorders-insights into current and future therapeutic perspectives","volume":"9","author":"Lucaciu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0530","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/jnc.13456","article-title":"In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity","volume":"136","author":"Luchtman","year":"2016","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0535","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1177\/1352458515574895","article-title":"FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis","volume":"21","author":"Luessi","year":"2015","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0540","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0545","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.4049\/jimmunol.178.6.3437","article-title":"Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3","volume":"178","author":"Maeda","year":"2007","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0550","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1177\/1352458517721355","article-title":"The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination","volume":"24","author":"Mannioui","year":"2018","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0555","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/scd.2015.0268","article-title":"The adipose mesenchymal stem cell Secretome inhibits inflammatory responses of microglia: Evidence for an involvement of Sphingosine-1-phosphate signalling","volume":"25","author":"Marfia","year":"2016","journal-title":"Stem Cells and Development"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0560","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","article-title":"Ponesimod: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0565","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000401","article-title":"Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate","volume":"4","author":"Mathias","year":"2017","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0570","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0460-z","article-title":"Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation","volume":"12","author":"Mazzola","year":"2015","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0575","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0580","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11910-011-0216-9","article-title":"Fingolimod for multiple sclerosis: Mechanism of action, clinical outcomes, and future directions","volume":"11","author":"Mehling","year":"2011","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0585","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e3181ebdd64","article-title":"Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis","volume":"75","author":"Mehling","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0590","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nature22352","article-title":"Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells","volume":"546","author":"Mendoza","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0595","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2353\/ajpath.2008.080478","article-title":"Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod","volume":"173","author":"Miron","year":"2008","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0600","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ana.21227","article-title":"FTY720 modulates human oligodendrocyte progenitor process extension and survival","volume":"63","author":"Miron","year":"2008","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0605","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.2353\/ajpath.2010.091234","article-title":"Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices","volume":"176","author":"Miron","year":"2010","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0610","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2014.02.001","article-title":"Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations","volume":"151","author":"Miyazaki","year":"2014","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0615","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1471-4159.2007.04629.x","article-title":"Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors","volume":"102","author":"Mullershausen","year":"2007","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051290","article-title":"Central modulation of selective sphingosine-1-phosphate receptor 1 ameliorates experimental multiple sclerosis","volume":"9","author":"Musella","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0625","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-01655-7","article-title":"Fingolimod in children with Rett syndrome: The FINGORETT study","volume":"16","author":"Naegelin","year":"2021","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0630","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000874","article-title":"Lymphocyte recovery after fingolimod discontinuation in patients with MS","volume":"7","author":"Nagy","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0635","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2012.12.005","article-title":"Fingolimod phosphate promotes the neuroprotective effects of microglia","volume":"256","author":"Noda","year":"2013","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0640","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1096\/fj.06-7420com","article-title":"Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration","volume":"21","author":"Novgorodov","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0645","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0650","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: A randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0655","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1074\/jbc.M610318200","article-title":"Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor","volume":"282","author":"Oo","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0660","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.neuropharm.2006.11.010","article-title":"Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors","volume":"52","author":"Osinde","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0665","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0494-x","article-title":"The dual S1PR1\/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures","volume":"13","author":"O\u2019Sullivan","year":"2016","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0670","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/jnc.14313","article-title":"Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia","volume":"144","author":"O\u2019Sullivan","year":"2018","journal-title":"J.Neurochem."},{"key":"10.1016\/j.pharmthera.2021.107971_bb0675","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1126\/science.1139221","article-title":"Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate","volume":"316","author":"Pappu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0680","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1046\/j.0953-816x.2001.01585.x","article-title":"Sphingosine-1-phosphate induces proliferation of astrocytes: Regulation by intracellular signalling cascades","volume":"13","author":"Pebay","year":"2001","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0685","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0690","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmed.2015.03.006","article-title":"Sphingosine 1-phosphate signaling at the blood-brain barrier","volume":"21","author":"Prager","year":"2015","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0695","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1161\/STROKEAHA.117.018505","article-title":"Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway","volume":"48","author":"Qin","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0700","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.4049\/jimmunol.1000568","article-title":"The origin and maturity of dendritic cells determine the pattern of sphingosine 1-phosphate receptors expressed and required for efficient migration","volume":"185","author":"Rathinasamy","year":"2010","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0705","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jmri.20057","article-title":"Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging","volume":"20","author":"Rausch","year":"2004","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0710","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0715","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00262-009-0775-7","article-title":"FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release","volume":"59","author":"Rolin","year":"2010","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0720","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1476-5381.2011.01579.x","article-title":"Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis","volume":"165","author":"Rossi","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0725","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1073\/pnas.1615413114","article-title":"Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation","volume":"114","author":"Rothhammer","year":"2017","journal-title":"Proceedings. National Academy of Sciences. United States of America"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0730","doi-asserted-by":"crossref","first-page":"47281","DOI":"10.1074\/jbc.M306896200","article-title":"Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability","volume":"278","author":"Sanchez","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0735","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderate-to-severe ulcerative colitis: Results from the open-label extension of the randomized, phase 2 touchstone study","volume":"15","author":"Sandborn","year":"2021","journal-title":"Journal of Crohn\u2019s & Colitis"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0740","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0745","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fimmu.2020.01459","article-title":"Three decades of interferon-beta in multiple sclerosis: Can we repurpose this information for the management of SARS-CoV2 infection?","volume":"11","author":"Severa","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2019.04.006","article-title":"A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in multiple sclerosis","volume":"101","author":"Severa","year":"2019","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0755","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaci.2014.01.037","article-title":"Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis","volume":"134","author":"Sic","year":"2014","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0760","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2008.12.018","article-title":"B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis","volume":"30","author":"Sinha","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0765","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bph.12938","article-title":"The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination","volume":"172","author":"Slowik","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0770","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.0b013e31820d9507","article-title":"The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators","volume":"76","author":"Soliven","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0775","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0780","doi-asserted-by":"crossref","first-page":"114465","DOI":"10.1016\/j.bcp.2021.114465","article-title":"Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function","volume":"186","author":"Spampinato","year":"2021","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0785","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133392","article-title":"Sphingosine 1 phosphate at the blood brain barrier: Can the modulation of S1P receptor 1 influence the response of endothelial cells and astrocytes to inflammatory stimuli?","volume":"10","author":"Spampinato","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0790","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri2974","article-title":"The outs and the ins of sphingosine-1-phosphate in immunity","volume":"11","author":"Spiegel","year":"2011","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0795","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09286-y","article-title":"Transcriptional dysregulation of Interferome in experimental and human multiple sclerosis","volume":"7","author":"Srinivasan","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0800","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1111\/bph.13557","article-title":"The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice","volume":"173","author":"Sun","year":"2016","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0805","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/0961203320966385","article-title":"Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study","volume":"29","author":"Tanaka","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0810","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.tp.0000281385.26500.3b","article-title":"FTY720 versus mycophenolate mofetil in de novo renal transplantation: Six-month results of a double-blind study","volume":"84","author":"Tedesco-Silva","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0815","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijdevneu.2003.09.003","article-title":"Microglial activation state and lysophospholipid acid receptor expression","volume":"21","author":"Tham","year":"2003","journal-title":"International Journal of Developmental Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0820","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-0817-6","article-title":"Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation","volume":"14","author":"Thomas","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0825","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1007\/s12325-020-01500-0","article-title":"Multiple-dose pharmacokinetics of ozanimod and its major active metabolites and the pharmacodynamic and pharmacokinetic interactions with pseudoephedrine, a sympathomimetic agent, in healthy subjects","volume":"37","author":"Tran","year":"2020","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0830","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86462","article-title":"Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation","volume":"1","author":"Tsai","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0835","doi-asserted-by":"crossref","first-page":"102290","DOI":"10.1016\/j.jaut.2019.06.001","article-title":"Myeloid sphingosine-1-phosphate receptor 1 is important for CNS autoimmunity and neuroinflammation","volume":"105","author":"Tsai","year":"2019","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0840","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fncel.2014.00396","article-title":"Neurogenesis in the embryonic and adult brain: Same regulators, different roles","volume":"8","author":"Urban","year":"2014","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0845","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0850","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0855","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.imbio.2009.06.003","article-title":"Regulation of macrophage function by sphingosine-1-phosphate","volume":"214","author":"Weigert","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0860","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3389\/fimmu.2019.02010","article-title":"Metabolic control of innate lymphoid cell migration","volume":"10","author":"Willinger","year":"2019","journal-title":"Frontiers in Immunology."},{"key":"10.1016\/j.pharmthera.2021.107971_bb0865","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-10-41","article-title":"Dual effects of daily FTY720 on human astrocytes in vitro: Relevance for neuroinflammation","volume":"10","author":"Wu","year":"2013","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0870","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134251","article-title":"Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis","volume":"5","author":"Wu","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0875","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ymthe.2016.12.008","article-title":"Effect of fingolimod on neural stem cells: A novel mechanism and broadened application for neural repair","volume":"25","author":"Zhang","year":"2017","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2021.107971_bb0880","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1582-4934.2007.00019.x","article-title":"FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury","volume":"11","author":"Zhang","year":"2007","journal-title":"Journal of Cellular and Molecular Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582100173X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582100173X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:21:16Z","timestamp":1759011676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582100173X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":176,"alternative-id":["S016372582100173X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107971","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons from S1P receptor targeting in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107971"}}